Blue Sky Asset Management LLC purchased a new stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) during the second quarter, Holdings Channel reports. The firm purchased 3,300 shares of the medical instruments supplier’s stock, valued at approximately $312,000.

A number of other large investors have also made changes to their positions in the stock. Burt Wealth Advisors raised its stake in shares of West Pharmaceutical Services by 38,540.0% in the first quarter. Burt Wealth Advisors now owns 1,932 shares of the medical instruments supplier’s stock valued at $158,000 after buying an additional 1,927 shares during the period. Harfst & Associates Inc. acquired a new stake in shares of West Pharmaceutical Services during the first quarter valued at about $186,000. CIBC Asset Management Inc acquired a new stake in shares of West Pharmaceutical Services during the second quarter valued at about $223,000. Tyers Asset Management LLC raised its stake in shares of West Pharmaceutical Services by 17.6% in the first quarter. Tyers Asset Management LLC now owns 2,464 shares of the medical instruments supplier’s stock valued at $201,000 after buying an additional 368 shares during the period. Finally, Cutler Group LP raised its stake in shares of West Pharmaceutical Services by 482.2% in the second quarter. Cutler Group LP now owns 2,550 shares of the medical instruments supplier’s stock valued at $241,000 after buying an additional 2,112 shares during the period. 91.35% of the stock is currently owned by hedge funds and other institutional investors.

Shares of West Pharmaceutical Services, Inc. (NYSE WST) opened at 86.36 on Thursday. The company has a market cap of $6.39 billion, a price-to-earnings ratio of 37.06 and a beta of 1.10. The firm has a 50-day moving average of $92.61 and a 200 day moving average of $88.81. West Pharmaceutical Services, Inc. has a one year low of $70.17 and a one year high of $99.91.

West Pharmaceutical Services (NYSE:WST) last posted its earnings results on Thursday, July 27th. The medical instruments supplier reported $0.66 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.01. West Pharmaceutical Services had a return on equity of 14.02% and a net margin of 11.42%. The company had revenue of $397.60 million during the quarter, compared to the consensus estimate of $406 million. During the same quarter last year, the firm earned $0.59 earnings per share. The company’s revenue was up 2.5% on a year-over-year basis. Equities research analysts anticipate that West Pharmaceutical Services, Inc. will post $2.69 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, November 1st. Stockholders of record on Wednesday, October 18th will be issued a dividend of $0.14 per share. The ex-dividend date of this dividend is Tuesday, October 17th. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.65%. This is an increase from West Pharmaceutical Services’s previous quarterly dividend of $0.13. West Pharmaceutical Services’s dividend payout ratio (DPR) is currently 22.22%.

TRADEMARK VIOLATION WARNING: “Blue Sky Asset Management LLC Invests $312,000 in West Pharmaceutical Services, Inc. (NYSE:WST)” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://www.watchlistnews.com/blue-sky-asset-management-llc-invests-312000-in-west-pharmaceutical-services-inc-nysewst/1467228.html.

Several equities research analysts have issued reports on the stock. BidaskClub lowered shares of West Pharmaceutical Services from a “sell” rating to a “strong sell” rating in a report on Thursday, August 3rd. Zacks Investment Research lowered shares of West Pharmaceutical Services from a “hold” rating to a “sell” rating in a report on Wednesday, July 19th. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $90.00 price target on shares of West Pharmaceutical Services in a report on Thursday, June 8th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the stock. West Pharmaceutical Services has a consensus rating of “Hold” and a consensus target price of $90.18.

In other news, CFO William J. Federici sold 54,996 shares of West Pharmaceutical Services stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $95.45, for a total transaction of $5,249,368.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.90% of the stock is currently owned by company insiders.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.